Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538105 | 0.76 | — | — | |
| SCHEMBL5544830 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL27487226 | 0.74 | EGLN1 (0.37) | KDM4EKDM5CPHF8KDM2A | |
| SCHEMBL692743 | 0.70 | — | — | |
| SCHEMBL1264310 | 0.69 | — | — | |
| Bicarbonate SCHEMBL19118378 | 0.68 | CYP1A2 (0.41) | KDM4EKDM5CPHF8KDM2A | |
| SCHEMBL8352247 | 0.68 | LDHA (0.50) | LDHASRRKDM4EKDM5CPHF8 | |
| SCHEMBL1639826 | 0.67 | — | — | |
| Malonic Acid SCHEMBL508810 | 0.67 | LDHA (0.53) | LDHASRRKDM4EKDM5CPHF8 | |
| SCHEMBL15131267 | 0.67 | CYP1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | claimed |
| EP-0793646-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016031-A1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| EP-2346498-B1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| CN-102209532-B | Method for reducing small, dense LDL particles | METABOLEX INC | 2015-07-22 | — | — | CN | disclosed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8669288-B2 | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-03-11 | — | — | US | disclosed |
| US-20030018082-A1 | Use of aminoguanidine or aminoguanidine analogs for the treatment of diseases of the nervous system | KADDURAH-DAOUK RIMA (US) | 2003-01-23 | — | — | US | disclosed |
| CN-1097580-C | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | BIOVITRUM AB (SE) | 2003-01-01 | — | — | CN | disclosed |
| CN-1377642-A | Use of compound for preparing medicine for curing and preventing non-insulin dependent diabetes or obesity | BIOVITRUM AB (SE) | 2002-11-06 | — | — | CN | disclosed |
| US-20020082448-A1 | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | THE UPJOHN COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6288124-B1 | Methods of inhibiting undesirable cell growth using an aminoguanidine compound | KADDURAH-DAOUK RIMA (US) | 2001-09-11 | — | — | US | disclosed |
| US-6169115-B1 | SUBSTRATES OR SUBSTRATE ANALOGS FOR CREATINE KINASE; | KADDURAH-DAOUK RIMA (US) | 2001-01-02 | — | — | US | disclosed |
| US-6166080-A | Aminoquanidine carboxylates for the treatment of obesity | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | LDHA 1606/4885SRR 2844/4885KDM4E 2996/4885 |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | LDHA 1606/4885SRR 2844/4885KDM4E 2996/4885 |
| US-20030018082-A1 | Use of aminoguanidine or aminoguanidine analogs for the treatment of diseases of the nervous system | PYGB, AGK, AK2 | LDHA 1213/4885SRR 2077/4885KDM4E 2650/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | LDHA 1606/4885SRR 2844/4885KDM4E 2996/4885 |
| US-20020082448-A1 | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | GPR119, IAPP, SLC5A2 | LDHA 1564/4885SRR 2498/4885KDM4E 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.